scholarly journals Using the Thickness Map from Macular Ganglion Cell Analysis to Differentiate Retinal Vein Occlusion from Glaucoma

2020 ◽  
Vol 9 (10) ◽  
pp. 3294
Author(s):  
Nam Ho Lee ◽  
Kee Sup Park ◽  
Han Min Lee ◽  
Jung Yeul Kim ◽  
Chang-sik Kim ◽  
...  
Keyword(s):  
Ganglion Cell ◽  
Retinal Vein Occlusion ◽  
Open Angle Glaucoma ◽  
Observer Agreement ◽  
Kappa Statistics ◽  
Cell Analysis ◽  
Diagnostic Specificity ◽  
Retrospective Case ◽  
Vein Occlusion ◽  
Ganglion Cell Analysis

Purpose: We hypothesized that the thickness map from macular ganglion cell analysis (GCA) acquired from spectral-domain optical coherence tomography can be used to differentiate retinal vein occlusion (RVO) from glaucoma. Methods: In this retrospective case control study, 37 patients with resolved RVO and 74 patients with primary open-angle glaucoma (POAG) were enrolled. Two independent examiners diagnosed patients with RVO or POAG based on the topographic pattern in the GCA thickness map. Inter-observer agreement for a decision between RVO and POAG was assessed using kappa statistics. Diagnostic specificity and accuracy were calculated. Results: Inter-observer agreement was good, with a kappa value of 0.765 (95% confidence interval, 0.634–0.896, p < 0.001). The diagnostic specificity of RVO from POAG using the GCA thickness map was 93.2% and diagnosis accuracy was 80.4%. Conclusions: An irregular GCA thickness map represents a simple and convenient differential diagnostic clue to distinguish RVO from POAG.

scholarly journals Primary open-angle glaucoma with retinal vein occlusion: a retrospective case series

2019 ◽  
Vol 1 (1) ◽  
pp. 50-59
Author(s):  
Muhamad Amin Ramli ◽  
Sarah Murniati Che Mat ◽  
Azhany Yaakub ◽  
Embong Zunaina ◽  
Liza Sharmini Ahmad Tajudin
Keyword(s):  
Retinal Vein Occlusion ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Case Series ◽  
Systemic Hypertension ◽  
Open Angle ◽  
Retrospective Case ◽  
Asian Patients ◽  
Vein Occlusion ◽  
End Stage

Glaucoma is a known risk factor for retinal vein occlusion (RVO). There are many reported studies among primary open-angle glaucoma (POAG) patients with RVO in Caucasians. Our objective was to report the natural course of RVO in Asian patients with POAG. A retrospective record review was conducted between January 2015 and December 2016 involving five POAG patients who developed RVO while attending regular follow-up at the Hospital Universiti Sains Malaysia glaucoma clinic (Malaysia). Three readings of intraocular pressure (IOP) were taken as pre-RVO IOP. IOP at presentation of RVO was also recorded. Clinical data including RVO management and complications were documented. All POAG patients were at the severe and end stage of the disease. None of them achieved target pressure. Median IOP at presentation was 26 ± 3.8 mmHg (SD) and the majority were asymptomatic. Systemic hypertension was present in all patients. There was deterioration of visual acuity and increased number topical medication post RVO presentation. Vigilant monitoring of IOP is important in POAG patients with systemic hypertension to prevent RVO, given that RVO in POAG is like robbing someone blind twice.  

scholarly journals Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series

2021 ◽  
Author(s):  
Imoro Zeba Braimah ◽  
Kofi Agyabeng ◽  
Winfried M. Amoaku
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Open Angle Glaucoma ◽  
Case Series ◽  
Retrospective Case ◽  
Foveal Thickness ◽  
Vein Occlusion ◽  
Treatment Naïve

Abstract Aim To evaluate the efficacy of ziv-aflibercept in Ghanaian patients with macular edema (ME) secondary to retinal vein occlusion (RVO). Methodology In this retrospective study, the medical records of patients with ME secondary to RVO who had been treated with intravitreal ziv-aflibercept (IVZ) (1.25 mg/0.05 ml), as part of routine clinical practice, on pro re nata basis with a minimum follow-up of 6 months were retrieved and analyzed. The main outcome measures are mean change in best-corrected visual acuity (BCVA) and central subfield foveal thickness (CSFT) measured on optical coherence tomography from baseline to 12 months post-IVZ, and ocular and systemic safety. Results Forty-three eyes were included in this study. Their mean age was 62.8 ± 11.9 years, 67.4% had at least 12-month duration of follow-up, 50% had primary open-angle glaucoma and 38 (88.4%) eyes were treatment naive. There was significant improvement in mean BCVA in LogMAR at 1 month post-initiation of IVZ (0.8 ± 0.5 vs. 1.1 ± 0.6), and visual improvement was maintained up to 12 months (p < 0.001). Eyes with ME following BRVO had better mean BCVA at baseline and on subsequent visits compared to eyes with CRVO/HRVO (p = 0.01). There was significant reduction in mean CSFT up to 12 months post-IVZ injection compared to baseline (p < 0.001). Ocular complications observed were consistent with complications associated with RVO. Conclusion We have observed significant improvement in functional and anatomic outcomes 12 months post-initiation of IVZ. There is the need to confirm long-term efficacy and safety of IVZ in a large prospective study.

scholarly journals Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy

2017 ◽  
Vol 8 (1) ◽  
pp. 271-278 ◽  
Author(s):  
Thomas Bertelmann ◽  
Hans Ulrich Frank ◽  
Hendrik Ansgar Fuchs ◽  
Nicolas Feltgen
Keyword(s):  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Retinal Thickness ◽  
Retrospective Case ◽  
Case Presentation ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Anti Vegf ◽  
Best Corrected Visual Acuity ◽  
Macular Ischemia

Purpose: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. Methods: Retrospective case presentation. Results: A 66-year-old female patient was treated with repeated intravitreal anti-VEGF injections due to ischemic ME following an acute BRVO. Over a period of 2.5 years best corrected visual acuity increased from 0.06 to 0.6 (decimal notation) accompanied by a reduction in central retinal thickness from 546 to 292 µm. Overall 17 anti-VEGF injections were administered to treat repeated recurrence of ME. Macular ischemia did not worsen during this profound intravitreal anti-VEGF therapy. Conclusion: Intravitreal anti-VEGF therapy can be a beneficial treatment strategy even in ischemic ME following an acute BRVO.

Sign in / Sign up

Export Citation Format

Share Document